Future studies, particularly those incorporating AD-specific biomarkers and accessible blood biomarkers such as glial fibrillary acidic protein to evaluate the severity of neuroinflammation [52], would be invaluable for determining the effects of eradication therapy on incident dementia. This evidence concerns the gene GFAP and Alzheimer disease.